TCGA-E2-A10A-01A-21R-A115-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 41
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.390
- INTERFERON_ALPHA_RESPONSE+0.380
- MITOTIC_SPINDLE+0.380
- E2F_TARGETS+0.360
- G2M_CHECKPOINT+0.310
- PROTEIN_SECRETION+0.300
- PI3K_AKT_MTOR_SIGNALING+0.210
- ANDROGEN_RESPONSE+0.190
- UV_RESPONSE_DN+0.180
- DNA_REPAIR+0.160
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.430
- KRAS_SIGNALING_DN-0.350
- IL6_JAK_STAT3_SIGNALING-0.320
- MYC_TARGETS_V2-0.300
- HEDGEHOG_SIGNALING-0.250
- CHOLESTEROL_HOMEOSTASIS-0.240
- PANCREAS_BETA_CELLS-0.220
- XENOBIOTIC_METABOLISM-0.200
- APICAL_SURFACE-0.170
- FATTY_ACID_METABOLISM-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A25C-01A-11R-A169-07 | — | B | 0.747 |
| 2 | TCGA-A7-A26J-01A-11R-A169-07 | — | B | 0.732 |
| 3 | SJEPD031367_D1.RNA-Seq | EPN | Anaplastic EPN | 0.718 |
| 4 | TCGA-B6-A1KN-01A-11R-A13Q-07 | — | C | 0.718 |
| 5 | TCGA-BH-A0C7-01B-11R-A115-07 | — | B | 0.716 |
| 6 | MNG180 | — | — | 0.699 |
| 7 | MDT-AP-3199 | Med | Medulloblastoma | 0.698 |
| 8 | MDT-AP-3245 | Med | Medulloblastoma | 0.696 |
| 9 | TCGA-MP-A4TF-01A-11R-A262-07 | — | cohortA4 | 0.679 |
| 10 | MNG1222 | — | — | 0.679 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.390 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.380 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |
| APOPTOSIS | 0.060 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.060 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.010 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.010 | Inavolisib | — uncovered |